Last reviewed · How we verify
MSB11022
MSB11022 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and inhibiting tumor growth.
MSB11022 is a biosimilar of trastuzumab that targets HER2-positive cancer cells by binding to the HER2 receptor and inhibiting tumor growth. Used for HER2-positive breast cancer, HER2-positive gastric cancer.
At a glance
| Generic name | MSB11022 |
|---|---|
| Also known as | Adalimumab |
| Sponsor | Fresenius Kabi SwissBioSim GmbH |
| Drug class | Monoclonal antibody (biosimilar) |
| Target | HER2 (human epidermal growth factor receptor 2) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
MSB11022 is a proposed biosimilar to trastuzumab (Herceptin), a monoclonal antibody that binds to the human epidermal growth factor receptor 2 (HER2) on cancer cells. By blocking HER2 signaling, it prevents cell proliferation and induces antibody-dependent cellular cytotoxicity (ADCC) in HER2-overexpressing tumors. As a biosimilar, it is designed to have comparable efficacy and safety to the reference trastuzumab product.
Approved indications
- HER2-positive breast cancer
- HER2-positive gastric cancer
Common side effects
- Cardiotoxicity / left ventricular dysfunction
- Infusion reactions
- Nausea
- Diarrhea
- Fatigue
Key clinical trials
- MSB11022 in Moderate to Severe Chronic Plaque Psoriasis (PHASE3)
- Comparison of PK and Tolerability of MSB11022 Administered by AI or PFS (PHASE1)
- MSB11022 in Moderate to Severe Rheumatoid Arthritis (PHASE3)
- MSB11022 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MSB11022 CI brief — competitive landscape report
- MSB11022 updates RSS · CI watch RSS
- Fresenius Kabi SwissBioSim GmbH portfolio CI